# US 2002/0161169 A1 · Hydrogel-forming system with hydrophobic and hydrophilic components

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0161169 A1
- Document ID: US20020161169A1
- Status: Published application
- Kind: A1
- Application number: 10/096,435
- Filed: 2002-03-13
- Published: 2002-10-31
- Earliest claimed: 1999-04-12
- Assignees: Cornell Research Foundation, Inc.
- Inventors: Chee-Youb Won; Yeli Zhang; Chih-Chang Chu
- Web page: https://patentgrep.com/patent/US20020161169A1

## CPC

- C08L 5/02: Dextran; Derivatives thereof
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C08B 37/0021: {Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran}
- C08G 18/6484: {Polysaccharides and derivatives thereof}
- C08G 18/8108: {having only one isocyanate or isothiocyanate group}
- C08L 67/07: having terminal carbon-to-carbon unsaturated bonds
- C08G 2210/00: Compositions for preparing hydrogels
- Y10S 525/937: Utility as body contact e.g. implant, contact lens or I.U.D.
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

A hydrogel forming system which comprises a hydrophobic macromer with unsaturated group terminated ends and a hydrophilic polymer which is a polysaccharide (e.g., dextran) containing hydroxy groups which are reacted with unsaturated group introducing compound, is convertible by free radical polymerization to form a hydrogel containing a three dimensional crosslinked polymer network containing hydrophobic and hydrophilic components. Agent can be entrapped in the polymer network, e.g., drugs, macromolecules or synthetic or natural polymers, for controlled release therefrom.

## Claims

### Claim 1

A hydrogel forming system which comprises hydrophobic and hydrophilic components which are convertible into a one phase crosslinked network structure by free radical polymerization.

### Claim 2

A hydrogel-forming system which comprises from 0.01 to 99.99% by weight of (A) a hydrophobic macromer with unsaturated group terminated ends, and from 99.99 to 0.01% by weight of (B) a hydrophilic polymer which is a polysaccharide containing hydroxy groups which are reacted with unsaturated group introducing compound; wherein the total of the percentages of (A) and (B) is 100%.

### Claim 3 (depends on 2)

The hydrogel-forming system according to claim 2 wherein the hydrophobic macromer is prepared by reacting the hydroxyls of a diol obtained by converting hydroxy of terminal carboxylic acid group of aliphatic polyester to aminoethanol group, with an unsaturated group introducing compound.

### Claim 4 (depends on 2)

The hydrogel-forming system according to claim 2 wherein the hydrophilic polymer is dextran wherein one or more hydroxyls in a glucose unit of the dextran is (are) reacted with an unsaturated group introducing compound.

### Claim 5 (depends on 2)

The hydrogel-forming system according to claim 2 wherein the hydrophillic polymer is dextran-maleic acid monoester.

### Claim 6 (depends on 2)

Hydrogel formed by the free radical polymerization of the hydrogel-forming system of claim 2 which has a three dimensional crosslinked polymer network structure containing hydrophobic and hydrophilic components.

### Claim 7 (depends on 6)

Hydrogel as claimed in claim 6 which has a drug of weight average molecular weight ranging from 200 to 1,000 entrapped in the three dimensional crosslinked polymer network.

### Claim 8 (depends on 7)

The hydrogel as claimed in claim 7 wherein the drug entrapped in the three dimensional network is indomethacin.

### Claim 9 (depends on 6)

Hydrogel as claimed in claim 6 which has a water-soluble macromolecule of weight average molecular weight ranging from 1,000 to 10,000 entrapped in the three dimensional crosslinked polymer network.

### Claim 10 (depends on 9)

The hydrogel as claimed in claim 9 wherein the water-soluble macromolecule is a polypeptide.

### Claim 11 (depends on 10)

The hydrogel as claimed in claim 10 wherein the polypeptide is insulin.

### Claim 12 (depends on 6)

Hydrogel as claimed in claim 6 which has a synthetic or natural polymer of weight average molecular weight ranging from 10,000 to 100,000 entrapped in the three dimensional crosslinked polymer network.

### Claim 13 (depends on 12)

The hydrogel as claimed in claim 12 wherein the synthetic or natural polymer is a protein.
